Resverlogix Corp. (FRA:RFS)

Germany flag Germany · Delayed Price · Currency is EUR
0.0540
-0.0015 (-2.70%)
At close: Jan 9, 2026
56.52%
Market Cap17.79M
Revenue (ttm)n/a
Net Income (ttm)-6.05M
Shares Outn/a
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume19,603
Open0.0540
Previous Close0.0555
Day's Range0.0540 - 0.0540
52-Week Range0.0190 - 0.1580
Betan/a
RSI42.06
Earnings DateMar 26, 2026

About Resverlogix

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Donald McCaffrey
Employees 19
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol RFS
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.